STA-9090 is a synthetic, small molecule HSP90 inhibitor. It has a unique chemical structure different from earlier HSP-90 inhibitors that, like IPI-504, are first generation drugs based on a family of antibiotics called ansamycins. As a result, STA-9090 is likely to have a different toxicity profile.
Written by Jim Hughes Updated five year adjuvant Gleevec trial: Phase II now open at 21 sites in the United States. NCT00867113 Updated MP470 trial in solid malignancies: Phase I updated to Ongoing as of 11/3/2009. NCT00894894 Added [...]
Here is a clinical trials update from December 2009 written by Jim Hughes United States RAD001 in combination with CP- 751,871 in patients with advanced sarcomas and other malignant neoplasms (NCT00927966) An mTOR inhibitor (RAD001) and [...]
